NCT06621381 Concentrated Exposure and Response Prevention for Children With Obsessive-compulsive Disorder
| NCT ID | NCT06621381 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Uppsala University Hospital |
| Condition | Obsessive-Compulsive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-09-11 |
| Primary Completion | 2029-12-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-09-11 with a primary completion date of 2029-12-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the preliminary outcomes of concentrated exposure and response prevention for children with obsessive-compulsive disorder (OCD) in regular clinical practice. It is a non-randomised open label evaluation where children 6-12 years with OCD who are patients at the Child and Adolescent Psychiatry (CAP) at Uppsala University Hospital will be rectruited together with their legal guardians. The treatment will be delivered by trained therapists in regular outpatient care. The main question the study aims to answer is: What are the preliminary treatment effects of concentrated exposure and response prevention with regards to OCD-symptoms, functional impact, family accomodation and clinician ratings of severity and improvement? Participants will receive psychoeducation (in group format) and exposure and response prevention (9-12h concentrated to one week, individual format). Outcomes will be measured on structured interviews, clinician ratings, and validated questionnaires pre-treatment, post-treatment and at a six month follow-up.
Eligibility Criteria
Inclusion Criteria: * The patient fulfills the diagnostic criteria of obsessive-compulsive disorder * The patient and the legal guardians have said yes to receiving the concentrated exposure with response prevention - treatment Exclusion Criteria: * The patient/legal guardians are unable to communicate in Swedish
Contact & Investigator
Vendela Zetterqvist, Ph D, Associate Professor
PRINCIPAL INVESTIGATOR
Uppsala University Hospital
Frequently Asked Questions
Who can join the NCT06621381 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 12 Years, studying Obsessive-Compulsive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06621381 currently recruiting?
Yes, NCT06621381 is actively recruiting participants. Contact the research team at vendela.zetterqvist@uu.se for enrollment information.
Where is the NCT06621381 trial being conducted?
This trial is being conducted at Uppsala, Sweden.
Who is sponsoring the NCT06621381 clinical trial?
NCT06621381 is sponsored by Uppsala University Hospital. The principal investigator is Vendela Zetterqvist, Ph D, Associate Professor at Uppsala University Hospital. The trial plans to enroll 20 participants.